Amgen's Just-Approved Migraine Drug Will Cost $6,900 a Year

(Bloomberg) -- Amgen Inc. will charge a lower-than-expected $6,900 a year for a novel migraine treatment that investors hope will become the biotechnology giant’s next blockbuster.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.